NCT02739360View on ClinicalTrials.gov

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

PHASE4TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

December 28, 2017

Study Completion Date

December 28, 2017

Conditions

Lymphoid Malignancies

Interventions

DRUG

Idelalisib

Idelalisib 150 mg tablet administered orally twice daily

Trial Locations (1)

Unknown

Amsterdam

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY